Key Highlights
- Loss per share was USD 0.23 against an estimate of a USD 0.20 loss.
- Net loss was USD 10.29 million, compared with USD 7.95 million.
- Research and development expense was USD 6.91 million, compared with USD 4.74 million.
- Cash was USD 9.45 million and marketable securities were USD 1.00 million.
Genelux Corporation (NASDAQ:GNLX) reported a third quarter 2026 net loss of USD 10.29 million, compared with USD 7.95 million in the prior-year quarter. Net loss per share was USD 0.23, compared with USD 0.21, against an estimate of a USD 0.20 loss.
The company describes itself as a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients with aggressive or difficult-to-treat tumor types. The filing reports no Revenue for the quarter.
Third Quarter Results
Research and development expense was USD 6.91 million, compared with USD 4.74 million, and general and administrative expense was USD 3.49 million, compared with USD 3.45 million. Total operating expenses were USD 10.40 million, compared with USD 8.19 million.
Interest income was USD 102 thousand, compared with USD 175 thousand, and bond accretion income was USD 10 thousand, compared with USD 69 thousand. Weighted average shares outstanding were 45,308,316, compared with 37,893,314.
Nine-Month Results
For the nine months ended September 30, 2026, Research and Development expense was USD 19.20 million, compared with USD 14.20 million, and general and administrative expense was USD 10.02 million, compared with USD 9.61 million. The net loss was USD 28.69 million, compared with USD 22.90 million.
Net loss per share for the nine months was USD 0.64, compared with USD 0.62.
Balance Sheet and Going Concern Disclosure
Cash was USD 9.45 million at September 30, 2026, compared with USD 5.33 million at December 31, 2025, and marketable securities were USD 1.00 million, compared with USD 9.26 million. Total Assets were USD 20.61 million, compared with USD 19.03 million.
Total liabilities were USD 11.43 million, compared with USD 7.48 million, and current liabilities were USD 9.40 million, compared with USD 6.23 million. The filing discloses substantial doubt about the company's ability to continue as a going concern, and the cover page reports 48,064,184 shares outstanding as of November 11, 2026.
Net cash used in Operating Activities for the nine months was USD 18.43 million, compared with USD 19.07 million. Stock-based compensation expense was USD 2.94 million for the quarter, compared with USD 2.64 million, and USD 6.99 million for the nine months, compared with USD 5.65 million.
Total current assets were USD 10.93 million, compared with USD 15.13 million at December 31, 2025, and total stockholders' Equity was USD 9.18 million, compared with USD 11.54 million. The accumulated Deficit was USD 312.22 million, compared with USD 283.54 million, and the filing states an accumulated deficit of USD 312.2 million. Depreciation expense for the nine months was USD 30 thousand, compared with USD 184 thousand.
Genelux Q3 2026 Earnings: Key Takeaways
Genelux reported a third quarter 2026 net loss of USD 10.29 million and a loss per share of USD 0.23. Cash was USD 9.45 million at September 30, 2026.






Please wait processing your request...